Ieramilimab
Ieramilimab
Ieramilimab (pronunciation: /ɪɛrəˈmɪlɪmæb/) is a novel monoclonal antibody designed for the treatment of various inflammatory diseases.
Etymology
The name "Ieramilimab" is derived from the International Nonproprietary Names (INN), where "Iera" represents the target, "li" stands for immunoglobulin, "m" for monoclonal antibody, and "ab" for antibody.
Function
Ieramilimab works by binding to a specific target on the surface of certain immune cells. This binding action can block the activity of these cells, reducing inflammation and potentially improving symptoms in patients with inflammatory diseases.
Related Terms
- Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Inflammatory Diseases: Diseases characterized by inflammation, such as rheumatoid arthritis and psoriasis.
- Immunoglobulin: A protein produced by plasma cells and lymphocytes and characteristic of these types of cells. Immunoglobulins play an integral role in the body's immune response by recognizing and binding to particular antigens, such as bacteria or viruses, and aiding in their destruction.
- Antibody: A blood protein produced in response to and counteracting a specific antigen. Antibodies combine chemically with substances that the body recognizes as alien, such as bacteria, viruses, and foreign substances in the blood.
External links
- Medical encyclopedia article on Ieramilimab
- Wikipedia's article - Ieramilimab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski